Ethical considerations of early (first vs. second trimester) risk assessment disclosure for trisomy 21 and patient choice in screening versus diagnostic testing

被引:12
|
作者
Sharma, Geeta
McCullough, Laurence B.
Chervenak, Frank A.
机构
[1] Cornell Univ, New York Presbterian Hosp, Weill Med Coll, Dept Obstet & Gynecol,Div Maternal Fetal Med, New York, NY 10021 USA
[2] Baylor Coll Med, Ctr Med Eth & Hlth Policy, Houston, TX 77030 USA
[3] New York Acad Med, Sect Obstet & Gynecol, New York, NY USA
[4] New York Obstet Soc, New York, NY USA
关键词
ethics; screening; risk assessment;
D O I
10.1002/ajmg.c.30118
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
We discuss the clinical implications regarding disclosure of risk assessment for trisomy 21 screening results in the first versus second trimester. Based on the ethical principles of respect for autonomy, beneficence, and justice, we argue that routinely offering first trimester risk assessment in centers qualified to provide it is ethically obligatory and routinely withholding the results of first trimester risk assessment is ethically unjustified. As risk for trisomy 21 occurs along a continuum, no pregnant woman is without risk; thus, offering diagnostic testing to all women is ethically justified. Informed consent and personal choice regarding diagnostic testing and termination of pregnancy shape patients' decisions to undergo first trimester risk assessment for trisomy 21. Appropriate counseling is required to allow for individual choice regarding timing of disclosure. (c) 2007 Wiley-Liss, Inc.
引用
收藏
页码:99 / 104
页数:6
相关论文
共 7 条
  • [1] Implementation of first-trimester risk assessment for trisomy 21: Ethical considerations
    Chervenak, FA
    McCullough, LB
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2005, 192 (06) : 1777 - 1781
  • [2] Two-stage first-trimester screening for trisomy 21 by ultrasound assessment and biochemical testing
    Kagan, K. O.
    Staboulidou, I.
    Cruz, J.
    Wright, D.
    Nicolaides, K. H.
    ULTRASOUND IN OBSTETRICS & GYNECOLOGY, 2010, 36 (05) : 542 - 547
  • [3] Follow-up frequency of testing in patients at very low risk for Trisomy 21 on first trimester screening
    Shamshirsaz, Alireza A.
    Ravangard, Samadh
    Shamshirsaz, Amirhoushang A.
    Egan, James
    Campbell, Winston A.
    Benn, Peter
    Borgida, Adam
    Janicki, Mary Beth
    Prabulos, Anne-Marie
    Ingardia, Charles
    Feldman, Debora
    Turner, Gary
    Zelop, Carolyn
    Timms, Diane
    Gurram, Padmalatha
    Fuller, Kisti
    Fang, Yu Ming Victor
    Billstrom, Rachel
    Lenehan, Kevin
    Sadowski, Allison
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2012, 206 (01) : S321 - S321
  • [4] Performance of second-trimester maternal biochemistry screening (quadruple test vs. triple test) for trisomy 21: An Indian experience
    Sablok, Aanchal
    Sharma, Akshatha
    Ahmed, Chanchal Singh
    Kaul, Anita
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2021, 154 (05) : 716 - 722
  • [5] Sequential screening for trisomy 21 by nuchal translucency measurement in the first trimester and maternal serum biochemistry in the second trimester in a low-risk population
    Schuchter, K
    Hafner, E
    Stangl, G
    Ogris, E
    Philipp, K
    ULTRASOUND IN OBSTETRICS & GYNECOLOGY, 2001, 18 (01) : 23 - 25
  • [6] Actual rates of recommended diagnostic testing after first trimester screening vs. same-day screening by cell free DNA
    Buresch, Arin
    Rosner, Mara
    Suskin, Barrie
    Einstein, Francine
    Bircaj, Emnonila
    Lister, Rolanda
    Klugman, Susan
    Dar, Pe'er
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2016, 214 (01) : S326 - S326
  • [7] Combined first trimester screening for trisomy 21: Assessment of excess risk in case of free ss-human chorionic gonadotrophin between 5 and 10 multiples of the median
    Atallah, Anthony
    Leport, Helene
    Sault, Corinne
    De La Fourniere, Benoit
    Huissoud, Cyril
    Cortet, Marion
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2023, 162 (02) : 676 - 683